The GPALPP1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line. This product offers a genetically disrupted pool targeting the GPALPP1 gene, leading to loss-of-function of the encoded G-patch domain-containing protein. The polyclonal nature provides a heterogeneous knockout background that more closely reflects population-level gene disruption, avoiding clonal bias and allowing the study of gene function within a mixed cellular context. This model is generated using non-viral CRISPR/Cas9-mediated gene disruption, resulting in ablation of GPALPP1 expression without additional selection markers, preserving the native cellular environment. It is suitable for researchers investigating the role of GPALPP1 in RNA metabolism and its implications in liver cancer biology.
The SK-HEP-1 cell line originates from the ascitic fluid of a male patient diagnosed with liver adenocarcinoma. These adherent cells display an epithelial morphology and co-express both endothelial and epithelial markers, making them a versatile model for studying hepatocellular carcinoma and adenocarcinoma of the liver. SK-HEP-1 cells are widely employed in cancer research due to their robust growth characteristics, ease of manipulation, and reproducible malignant phenotype. Their unique dual phenotype facilitates the investigation of tumor cell plasticity, metastasis, and endothelial-like properties within a hepatic cancer context, providing a biologically relevant platform for functional genomics and drug discovery studies.
GPALPP1 encodes a putative RNA-binding protein characterized by a G-patch domain, a motif known to function in RNA processing and spliceosome dynamics. Although the precise physiological role of GPALPP1 remains poorly defined, it is predicted to participate in pre-mRNA splicing and RNA metabolism. The protein interacts with the DEAH-box helicase DHX15 and core spliceosomal components including PRPF8 and SNRNP200, suggesting its involvement in spliceosome assembly and catalytic activation. GPALPP1 likely modulates splicing of transcripts governing cell proliferation and apoptotic programs, thereby influencing downstream pathways critical for tumor cell survival. Its association with spliceosomal snRNPs U1, U2, U4/U6, and U5 further underscores its integration into the macromolecular splicing machinery.
In the SK-HEP-1 liver cancer model, disruption of GPALPP1 through CRISPR/Cas9 gene editing has the potential to perturb spliceosome function, leading to widespread alterations in alternative splicing patterns. Such splicing dysregulation is a hallmark of cancer, often driving oncogenic transformation by generating isoforms that enhance proliferation, evade apoptosis, or promote invasion. The knockout of GPALPP1 in this cell background provides a direct tool to interrogate how loss of this splicing factor affects malignant phenotypes. Considering the intrinsic endothelial-like characteristics of SK-HEP-1, this model also enables dissection of splicing-dependent mechanisms in tumor angiogenesis and transdifferentiation processes, which are relevant to hepatocellular carcinoma progression.
This polyclonal GPALPP1 knockout pool is engineered for a spectrum of advanced research applications. It can be utilized to characterize GPALPP1-dependent splicing events via RNA sequencing, validate target transcripts through RT-qPCR, and confirm loss of protein expression by Western blotting. Functional assays such as cell proliferation, apoptosis, migration, and invasion studies can elucidate the phenotypic consequences of GPALPP1 ablation. Additionally, the model serves as a screening platform for small-molecule splicing inhibitors or therapies targeting spliceosomal vulnerabilities in liver cancer. Drug sensitivity analyses may reveal synthetic lethal interactions or resistance mechanisms. For further details or technical support, please contact Ascent Research.
